BR100 Decreased By (-0.22%)
BR30 Decreased By (-0.55%)
KSE100 Decreased By (-0.16%)
KSE30 Decreased By (-0.14%)
AGHA 6.71 Increased By ▲ 0.03 (0.45%)
BECO 4.39 Increased By ▲ 0.02 (0.46%)
BML 56.75 Decreased By ▼ -0.57 (-0.99%)
BOP 30.22 Decreased By ▼ -0.13 (-0.43%)
CNERGY 13.04 Decreased By ▼ -0.08 (-0.61%)
CSIL 5.38 Decreased By ▼ -0.03 (-0.55%)
FCCL 52.62 Decreased By ▼ -0.17 (-0.32%)
FFL 14.59 Decreased By ▼ -0.13 (-0.88%)
FNEL 1.12 No Change ▼ 0.00 (0%)
KEL 6.17 Increased By ▲ 0.08 (1.31%)
KOSM 5.96 Increased By ▲ 0.23 (4.01%)
LOTCHEM 26.45 Decreased By ▼ -0.01 (-0.04%)
MLCF 92.65 Decreased By ▼ -0.51 (-0.55%)
NBP 164.70 Increased By ▲ 0.04 (0.02%)
NCPL 55.11 Decreased By ▼ -0.55 (-0.99%)
NPL 59.89 Decreased By ▼ -1.27 (-2.08%)
OGDC 315.39 Decreased By ▼ -1.34 (-0.42%)
PACE 9.93 Increased By ▲ 0.06 (0.61%)
PAEL 35.22 Decreased By ▼ -0.41 (-1.15%)
PIBTL 14.75 Increased By ▲ 0.07 (0.48%)
PPL 223.75 Decreased By ▼ -3.16 (-1.39%)
PRL 92.16 Decreased By ▼ -0.86 (-0.92%)
PTC 60.39 Increased By ▲ 0.13 (0.22%)
SSGC 23.70 Decreased By ▼ -0.11 (-0.46%)
TBL 8.80 Increased By ▲ 0.05 (0.57%)
TELE 7.68 Decreased By ▼ -0.12 (-1.54%)
TPL 22.30 Decreased By ▼ -0.05 (-0.22%)
TPLP 12.70 Decreased By ▼ -0.27 (-2.08%)
TREET 22.15 Decreased By ▼ -0.01 (-0.05%)
TRG 56.42 Decreased By ▼ -0.14 (-0.25%)
World

German experts recommend AstraZeneca vaccine only for over 60s

*"After several consultations, STIKO, with the help of external experts, decided by a majority to recommend the AstraZeneca COVID-19 vaccine only for persons aged 60 years and older on the basis of available data on the occurrence of rare but very severe thromboembolic side effects," it said.
Published Updated
By

BERLIN: Germany's vaccine committee, known as STIKO, on Tuesday recommended using AstraZeneca's COVID-19 vaccine only for people aged 60 and over.

"After several consultations, STIKO, with the help of external experts, decided by a majority to recommend the AstraZeneca COVID-19 vaccine only for persons aged 60 years and older on the basis of available data on the occurrence of rare but very severe thromboembolic side effects," it said.

"Regarding the question of administering the second vaccine dose to younger persons who have already received a first dose of the AstraZeneca COVID-19 vaccine, STIKO will issue a supplementary recommendation by the end of April," it added in a statement.

Comments

Comments are closed for this article.